2026年10月16日星期五
M
Catatan Universal
Berita Kilat Global
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

Global pharma firms walk back innovative drug investments in Japan

Sumber 日经 Nikkei Asia3 jam lalu
Ringkasan konten

Global pharma firms walk back innovative drug investments in Japan

Situs ini hanya menyediakan indeks judul dan ringkasan, konten lengkap dan hak cipta sepenuhnya milik penerbit asli, silakan klik tautan asli untuk membaca.

Buka artikel asli
Saluran terkait
Ekonomi
Wilayah terkait
Jepang
Bahasa asli
English
Nomor entri
business-839627c8

Comments 0 comments

No comments yet. Be the first.

Global pharma firms walk back innovative drug investments in Japan · Catatan Universal